MEI Pharma presents new clinical data on ME-401
MEI Pharma announced that updated data presented at ASCO 2019 from a Phase 1b study of investigational ME-401, a selective oral inhibitor of PI3K delta, demonstrate an 80% overall response rate in patients with relapsed or refractory follicular lymphoma. Additionally, the data demonstrate: Comparable overall response rates, ranging from 75%-83%, across patient groups receiving ME-401 as a monotherapy or in combination with rituximab, and in patient groups dosed with ME-401 once daily on a continuous schedule or on an intermittent schedule of once daily for the first 7 days of a 28-day cycle after 2 months of continuous dosing. A lower rate of delayed, grade 3 adverse events observed in patients in the IS group. Durable responses in both CS and IS groups with no median yet reached.